OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.
Part of a story that several outlets report: OpenAI acquires Orchestra Bio for drug development
Get smart on it
OpenAI acquired Orchestra Bio, a four-year-old AI biotech software startup, to strengthen its life sciences capabilities. Orchestra creates AI agents that help biotech companies manage drug discovery operations, including financial tracking and clinical trial scheduling. OpenAI plans to integrate Orchestra's team and technology into Rosalind, its AI model for life sciences research, and the Rosalind Workbench tool that helps researchers plan experiments and analyze results. This acquisition reflects a broader trend where major AI labs are building specialized software for large industries like pharmaceuticals, absorbing startups rather than displacing them with competing features.
Relevant courses
Want to go deeper than the news? Explore live, cohort-based AI courses taught by practitioners.
Browse AI courses on MavenRelated news
OpenAI working on new $30B raise at $1.25T valuation ahead of IPO
Should OpenAI command an over $1 trillion valuation with this round, it would break records as the most highly valued private company ever.
Also reported by SiliconANGLE and The Decoder
DeepSeek reportedly raises $15B days after US restrictions
DeepSeek has reportedly raised $15 billion in one of China's largest funding rounds, just days after the US ordered federal agencies to remove its technology over national security concerns.
Eka Robotics raises $150M to scale its vision-force-action model for robots
Eka says its model can generalize across objects, tasks, and environments. | Source: Eka Robotics Eka Robotics this week said it has raised $150 million in Series A funding. The startup said the new funding will help it scale its technology and customer deployments. Founded in 2024, Eka is building a vision-force-action (VFA) model to develop an intuition of physics through reinforcement learning at scale. The Cambridge, Mass.-based company said that robots using its AI can pick a wide variety o
Otter.ai raises $320M in funding for its AI meeting assistant
Otter.ai Inc., the developer of a popular artificial intelligence meeting assistant, today announced that it has raised $320 million in funding. The capital came entirely from General Catalyst’s Customer Value Fund. The investment vehicle provides startups with financing for sales and marketing initiatives. General Catalyst doesn’t take a stake in portfolio companies, but instead receives […] The post Otter.ai raises $320M in funding for its AI meeting assistant appeared first on SiliconAN
AI drug development startup Pathos AI closes $237M investment
Pathos AI Inc. today announced that it has raised $237 million in funding at a $3 billion valuation. Pharmaceutical giant Bristol Myers Squibb Co. led the Series E round with participation from several unnamed returning backers. Pathos’ investor roster includes big names such as AstraZeneca plc, NEA and General Atlantic. Pathos is developing cancer drugs […] The post AI drug development startup Pathos AI closes $237M investment appeared first on SiliconANGLE.
Meta to create a new class of shares to fund AI push
Meta says it's issuing a new class of shares to fund its AI initiatives. As part of its third-quarter earnings report released on Wednesday, the company says the non-voting stock will also go toward potential acquisitions and employee compensation, with trading beginning in 2027. "The scale of investment required to compete, sustain growth, expand infrastructure, and pursue new strategic initiatives amidst the AI transformation taking place in the industry is significant," Meta
Also reported by TechCrunch